MK
Therapeutic Areas
Crinetics Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Paltusotine (CRN00808) | Acromegaly | Phase 3 |
| CRN04894 | Cushing's Disease | Phase 2 |
| CRN04777 | Hyperinsulinism | Phase 1 |
| CRN01941 | Neuroendocrine Tumors (NETs) | Preclinical |
Leadership Team at Crinetics Pharmaceuticals
RS
R. Scott Struthers, Ph.D.
Founder & Chief Executive Officer
SF
Stephen F. Betz, Ph.D.
Founder & Chief Scientific Officer
GA
Garlan Adams, J.D.
Chief Legal Officer
AC
Adriana C. Cabré
Chief Human Resources Officer
OH
Omar Hamdy, Ph.D.
Senior Vice President, Chief of Staff & Head of Portfolio Strategy
IK
Isabel Kalofonos
Chief Commercial Officer
JK
Jacqueline Kirby
Chief Corporate Affairs Officer
JK
Jeff Knight, M.P.H.
Chief Development & Operating Officer
AS
Alan S. Krasner, M.D.
Chief Endocrinologist
CR
Chris Robillard
Chief Business Officer